Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization (PEDD-UFE)
Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization Via Pressure-Enabled Drug Delivery With the TriNav Infusion System (PEDD-UFE)
Sponsor: Massachusetts General Hospital
Terminated
Insufficient Enrollment
Other terminated trials from Massachusetts General Hospital
A NA clinical study on Uterine Bleeding and Uterine Fibroid, this trial is terminated or withdrawn. The trial is conducted by Massachusetts General Hospital and has accumulated 5 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
May 2025 — Present [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2024 — May 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Mar 2024 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Mar 2024 [monthly]
Not Yet Recruiting NA
First recorded
Feb 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
- TriSalus Life Sciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .